INTRODUCTION

The glutamate hypothesis emphasizes possible dysfunctions in glutamatergic signaling, typically those of the ionotropic N-methyl-D-aspartate (NMDA) receptor, in the central nervous system of schizophrenia patients. Human studies have shown that the acute administration of noncompetitive NMDA receptor antagonists, phencyclidine, and ketamine causes hallucinations and delusions seen in the early stages of schizophrenia patients. NMDA receptor blockades also cause negative psychological states and worsen already expressed cognitive and psychological symptoms in schizophrenia patients. Furthermore, a recent genome-wide association
study (GWAS) has identified 108 sites on the human genome that are closely associated with schizophrenia and genes related to glutamatergic neurotransmission, such as GluN2A (GRIN2A), which is a subtype of NMDA receptors.\(^7\)

Acute administration of NMDA receptor antagonists is one of the pharmacological animal models of schizophrenia inspired by the glutamatergic hypothesis. This animal model has shown various schizophrenic behavioral phenotypes: (1) impaired sensorimotor gating in the prepulse inhibition test.\(^8\) (2) Hyperactivity and stereotyped behavior in the open field test,\(^9\) which is regarded as a potential model of the positive symptoms of schizophrenia.\(^10\) (3) Social withdrawal, which is an example of a negative symptom.\(^11\) (4) Cognitive dysfunction in behavioral set-shifting,\(^12\) reversal learning,\(^13\) and paired-associate learning.\(^14\)

In addition to the symptoms mentioned above, schizophrenia patients show dysfunctional decision-making associated with flexible goal-directed behavior.\(^15\)\(^,\)\(^16\) Goal-directed behavior is an intentionally executed action that is based on the association between a specific action and causal outcome. Previous studies have quantified goal-directed behavior in an outcome-specific devaluation paradigm in both human and animal subjects.\(^17\)\(^,\)\(^18\) In this behavioral paradigm, subjects are first trained in an instrumental conditioning task, where a specific outcome (eg, food) is delivered after the execution of a specific action (eg, button pressing). Goal-directed behavior is measured as the reduction in the likelihood of taking action after the outcome is devalued by the specific satiety or paired with an unpleasant stimulus. Indeed, schizophrenia patients show difficulty in a flexible behavioral change based on updated outcome values in a devaluation paradigm.\(^20\)

The animal model of acute pharmacological blockade of NMDA receptors has shown suboptimal value-based decision making.\(^21\) However, it has not been tested whether this animal model of schizophrenia exhibits an impaired goal-directed behavior in an outcome-specific devaluation paradigm. In the present study, we investigated the effects of the acute administration of an NMDA receptor antagonist, MK-801 (dizocilpine; 5-methyl-10.11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine), on instrumental food-seeking behavior after outcome devaluation.

## 2 METHODS

Twenty-four male Long-Evans rats (8 weeks old) were used. The mean body weight at the start of the experiments was around 280 g. Ten rats were assigned to experiment 1. Fourteen rats were assigned to experiment 2 and experiment 3. However, three rats were removed after the experiment 2 because of health issues. Rats were housed in individual cages on a 12:12 h light-dark cycle (light on: 0800-2000) with free access to water throughout the experiments. Their feeding was limited to maintain 85%-90% of their expected free-feeding weight. All efforts were made to minimize the number of animals used and their suffering. All experiments were approved by the University of Tsukuba Committee on Animal Research.

In the present study, we used MK-801, which is a common and easy-to-use NMDA receptor antagonist, compared to phencyclidine and ketamine that are often regarded as the controlled substances. (-)-MK-801 hydrogen maleate (MK-801; Sigma) was diluted in saline (SAL; Otsuka, Tokyo, Japan) to a final concentration of 0.1 mg/mL. In the experiment, the dose of 0.1 mg/kg was intraperitoneally injected. This low dose of MK-801 was chosen based on a previous report which showed that this dose of MK-801 had no effects on simple discriminative behaviors and motor functions.\(^22\)

In experiment 1, we tested whether satiety for a specific food (sucrose or lipid) induced food-specific devaluation in a free consumption test (Figure 1A). This test consisted of two free consumption periods. In the first period, the food-restricted rat was put in a transparent plastic cage (38 × 21 × 20 cm) and allowed to freely access either sucrose pellets (45 mg, 5TUT; Test Diet) or a 10% soybean lipid solution (Intralipos) for 60 min. The second free food consumption was conducted immediately after the first one in the same manner but only for 10 min. The amounts of food consumed were measured after both periods. Free consumption tests were repeated four times in a within-subject design so that each rat experienced all combinations of devalued food (sucrose or lipid) and tested food (sucrose or lipid). The order of food consumed in each test was counterbalanced.

In experiment 2, we tested whether the satiety for sucrose-induced outcome-specific devaluation in both lever-press operant conditioning and free consumption tests (Figure 1C). After 2 days of handling (5 min), rats were allowed to freely explore in an operant chamber (30 × 32 × 36 cm; O’Hara & Co., Ltd.) for 10 min. During this habituation period, rats were able to eat sucrose pellets piled at a food reward port. After the habituation period, rats were given a 2-day magazine training for 30 min. A house light and a mild background white noise were turned on when the training started, and a single pellet was passively delivered to the food reward port every 60 s on average (RT-60 s schedule). Following the magazine training, a single nonretractable lever was set on the wall at the opposite side of the food reward port, and rats were trained to press the lever to get the sucrose rewards for 9 days. Each session finished when rats earned 30 rewards or when 30 min elapsed. In the first 3 days, rats were trained in a continuous reinforcement schedule (CRF), in which a single lever press results in a single sucrose pellet delivery. For the remaining 6 days, rats were trained in a random ratio (RR) schedule where rats were able to earn the reward by pressing the lever with a probability of 0.2 (RR5), 0.1 (RR10), or 0.05 (RR20). Each RR schedule training was conducted for 2 days. After a sufficient lever-press training, rats were tested in a lever press-based outcome-specific devaluation paradigm consisting of 3 periods: devaluation, lever-press test, and free consumption test. On the day of the devaluation test, rats were first allowed to eat lever-press-associated sucrose pellets or a control 10% lipid solution for 60 min in the same manner as the experiment 1 (devaluation). Immediately after the devaluation period, the lever-press test was conducted, where lever-press behavior was measured for 3 min under an extinction condition (ie, no reward delivery) in the operant chamber. Subsequently, rats were moved to a normal cage, and then the amount of sucrose pellet consumed was assessed...
(free consumption test). This devaluation test was repeated twice so that rats’ food-seeking behavior after satiety by both sucrose and lipid could be assessed.

In experiment 3, the effect of systemic injection of an NMDA receptor antagonist on outcome specific devaluation was tested using the same animals as those used in experiment 2. The procedure of
drug tests was the same as that of the devaluation test; however, rats received intraperitoneal injection of MK-801 or SAL immediately after the devaluation period (Figure 1H). Drug tests were repeated four times so that rats were tested in all four different conditions of devaluation (devalue vs value) and drug treatments (MK-801 vs SAL). The order of each condition was counterbalanced among animals.

In this study, averages of behaviors in different conditions were compared using either of a paired t test, one-way repeated measures ANOVA, or two-way repeated measures ANOVA (devaluation × drug) followed by a Bonferroni comparison (P < .05). In experiment 3, the percentage of animals showing devaluation between drug conditions was compared using Fisher’s exact test. An animal was regarded as “showing devaluation” when it showed a lower lever press or food consumption under the devalued condition compared to the valued condition. All statistical analyses were performed using Prism 9.2.0 (GraphPad Software).

3 | RESULTS

The result of experiment 1 is shown in Figure 1B. Free food consumption for 60 min in the first period was sufficient to induce food-specific devaluation in the second free consumption period. According to two-way repeated measures ANOVA, there was a significant main effect of devaluation [F(1, 9) = 34.24, P < .001]. The amount of each food consumed decreased when the food was devalued.

Results of experiment 2 are shown in Figure 1D, F, G. In Figure 1D, the number of lever presses per min is shown. One-way repeated measures ANOVA revealed that there was a significant main effect of training days [F(10, 130) = 44.59, P < .001]. Results of the lever-press test and the free consumption test are shown in Figure 1F, G, respectively. Sixty-min free consumption of sucrose pellets induced outcome-specific devaluation in the operant conditioning and the free consumption test. A paired t test revealed that the number of lever presses during the lever-press test [t(13) = 4.2056, P < .01] and the amount of sucrose pellet consumption during the free consumption test [t(13) = 3.8256, P < .01] significantly decreased when sucrose was devalued.

Results of experiment 3 are shown in Figure 1H, I, J, K, L. MK-801 impaired outcome-specific devaluation in the lever-press operant conditioning, but not in the free consumption test. According to two-way repeated measures ANOVA, there were significant main effect of devaluation [F(1, 10) = 44.44, P < .001], main effect of drug administration [F(1, 10) = 19.97, P < .001], and their interaction [F(1, 10) = 10.65, P < .01] in the lever-press test (Figure 1I). Subsequent post hoc analysis revealed that the number of lever presses in the SAL-devalued condition was less than that in the SAL-valued condition (P < .001). It was also revealed that the number of lever presses in the MK-801-valued condition is less than that in the SAL-valued condition (P < .01). Furthermore, Fisher’s exact test revealed that fewer animals showed successful devaluation under the MK-801 condition (P < .05) (Figure 1J). Regarding the free consumption test, two-way repeated measures ANOVA revealed significant main effects of devaluation [F(1, 10) = 99.96, P < .001] and drug administration [F(1, 10) = 5.13, P < .05] (Figure 1K). The amount of sucrose pellets consumed in the devalued condition was lower than that of the devalued condition. Also, the amount of sucrose pellets consumed in the MK-801 condition was higher than that in the SAL condition. In the free consumption test, all animals showed a successful devaluation regardless of drug conditions (Figure 1L).

4 | DISCUSSION

This study investigated goal-directed behavior in a pharmacological animal model of schizophrenia induced by an NMDA receptor blockade. As results, it was found that the acute administration of MK-801 impaired the satiety-induced devaluation when it was measured in the lever-press operant conditioning task, but not in subsequent free consumption test. Our results suggest that acute NMDA receptor blockade is a useful rodent animal model to investigate an impaired value-related decision making in schizophrenia.

In this study, treatment of MK-801 decreased the overall frequency of lever presses compared to the control condition. This result seems to indicate potential nonspecific effects of MK-801 on general cognitive functions or on the motivation for food. However, the dose (0.1 mg/kg) of MK-801 used in our study does not impair discriminative behavior and working memory in rats. Furthermore, the free consumption test following the lever-press test revealed that the amount of food intake significantly decreased in the devalued condition regardless of drug treatment, and MK-801 treatment rather increased general sucrose pellet consumption. These results suggest that MK-801 does not impair general motivation for food nor satiety-induced value updating. To summarize, MK-801 impairs the expression of goal-directed behavior in operant conditioning by...
disrupting action-outcome association but not due to its nonspecific side effects.

The systemic MK-801 injection is likely to impair goal-directed behavior by disrupting glutamatergic neurotransmission in the specific regulatory brain area. The striatum, especially the dorsomedial part, is an essential brain structure in regulating goal-directed behavior. While the activation of NMDA receptors and its downstream signaling pathway in the dorsomedial striatum is particularly important for the acquisition of action-outcome association, the activity of striatal NMDA receptors may also have some role in the execution of goal-directed behavior, which depends on the action-outcome memory. In addition, the insular cortex is also known to regulate the expression of outcome-specific devaluation. Intra-insular injection of an NMDA receptor antagonist eliminates selective devaluation, suggesting that NMDA receptors in the insular cortex are involved in the expression of goal-directed behavior.

NMDA receptor blockade also changes the level of various neurotransmitters in the brain. Indeed, the systemic MK-801 injection induces significant dopamine, serotonin, and noradrenaline release in the striatum and cortex. Moreover, MK-801 decreases the reuptake of serotonin and noradrenaline. These findings suggest that MK-801-induced excessive monoamine release in the cortico-basal ganglia circuit may cause the impaired goal-directed behavior observed in the present study. Given that the dysfunction in the cortico-striatal circuit is associated with impaired goal-directed behavior in schizophrenia, further research is needed to investigate the relationship between kinetics of neurotransmitters caused by NMDA receptor hypofunction and disrupted optimal value-based decision-making.

ACKNOWLEDGMENTS
We thank MN Daudelin for comments on earlier versions of the manuscript. This study was supported by grants from JSPS KAKENHI (19K21806 for KY, TO, YI, 19K21808 for TO, 19K03385 for TO, 19H01769 for TO, 19H05005 for TO, 21H00311 for TO, and 21K18557 for TO), HOKUTO Foundation for the Promotion of Biological Science (No grant number) for TO, Uehara Memorial Foundation (No grant number) for TO, Takeda Science Foundation (No grant number) for TO, The Mitsubishi Foundation (No. 202011006) for TO, Kowa Life Science Foundation (No grant number) for TO, Research Foundation for Opto-Science and Technology (No grant number) for TO, and The Salt Science Research Foundation (No. 2146) for TO.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
TO conceptualized and designed experiments. TI performed the behavioral tests. TO and TI analyzed the data and wrote the manuscript. KY and YI helped to draft the manuscript. KY and YI supervised all aspects of the present study. All authors have read and approved the final manuscript.

ANIMAL STUDIES
Animal experiments were approved by the University of Tsukuba Committee on Animal Research.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available in the supplementary material of this article.

ORCID
Kazuo Yamada https://orcid.org/0000-0003-2249-2037

REFERENCES
1. Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73:204–15. https://doi.org/10.1111/pcn.12823
2. Nakazawa K, Sapkota K. The origin of NMDA receptor hypofunction in schizophrenia. Pharmacol Ther. 2020;205:107426. https://doi.org/10.1016/j.pharmthera.2019.107426
3. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney RE, BREMMER JD, et al. Subanesthetic effects of the noncompetitive nmda antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199–214. https://doi.org/10.1001/archpsyc.1994.03950030035004
4. Javitt DC, ZUKIN SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301–8. https://doi.org/10.1176/ajp.148.10.1301
5. Lahti AC, KOFFEL B, LAPORTE D, TAMMINGA CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 1995;13(1):9–19. https://doi.org/10.1016/0893-133X(94)00131-I
6. MALHOTRA AK, PINS DA, ADLER CM, ELMAN I, CLIFTON A, PICKAR D, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 1997;17:141–50. https://doi.org/10.1016/S0893-133X(97)00036-5
7. Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, HOLMANS PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7. https://doi.org/10.1038/nature13595
8. MANAHAN-VAUGHAN D, von Haebler D, Winter C, JUCKEL G, Heinemann U. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus. 2008;18:125–34. https://doi.org/10.1002/hipo.20367
9. Ögren SO, Goldenstein M. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology. 1994;11:167–77. https://doi.org/10.1038/sj.npp.1380103
10. Adell A, Jiménez-Sánchez L, López-Gil X, Romón T. Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophr Bull. 2012;38:9–14. https://doi.org/10.1093/schbul/sbr133
11. Savage S, Kehr J, Olson L, Mattsson A. Impaired social interaction and enhanced sensitivity to phencyclidine-induced deficits in novel object recognition in rats with cortical cholinergic denervation. Neuroscience. 2011;195:60–9. https://doi.org/10.1016/j.neuroscience.2011.08.027
12. Egerton A, Reid L, Mckerchar CE, Morris BJ, Pratt JA. Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology. 2005;179:77–84. https://doi.org/10.1007/s00213-004-2109-y
13. Idris NF, Repeto P, Neill JC, Large CH. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology. 2005;179:336–48. https://doi.org/10.1007/s00213-004-2058-5

14. Roebuck AJ, Marks WN, Liu MC, Tahir NB, Zabder NK, Snutch TP, et al. Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801. Psychopharmacology. 2018;235:3339–50. https://doi.org/10.1007/s00213-018-5040-3

15. Sterzer P, Voss M, Schlagenhauf F, Heinz A. Decision-making in schizophrenia: a predictive-coding perspective. NeuroImage. 2019;133–43. https://doi.org/10.1016/j.neuroimage.2018.05.074

16. Griffiths KR, Morris RW, Balleine BW. Translational studies of goal-directed action as a framework for classifying deficits across psychiatric disorders. Front Syst Neurosci. 2014;8:1-16. https://doi.org/10.3389/fsysn.2014.00101

17. Simmler LD, Ozawa T. Neural circuits in goal-directed and habitual behavior: implications for circuit dysfunction in obsessive-compulsive disorder. Neurochem Int. 2019;129:104464. https://doi.org/10.1016/j.neuint.2019.104464

18. Dickinson A, Balleine B. Motivational control of goal-directed action. Anim Learn Behav. 1994;22:1-18. https://doi.org/10.1037/0375-BFO3199951

19. Balleine BW, Dickinson A. Goal-directed instrumental action: Contingency and incentive learning and their cortical substrates. Neuropharmacology. 1998;37:407-19. https://doi.org/10.1016/S0028-3908(98)00033-1

20. Morris RW, Quail S, Griffiths KR, Green MJ, Balleine BW. Corticostratial control of goal-directed action is impaired in schizophrenia. Biol Psychiatry. 2015;77:187–95. https://doi.org/10.1016/j.biopsych.2014.06.005

21. Yates JR, Breitenstein KA, Gunkel BT, Hughes MN, Johnson AB, Rogers KK, et al. Effects of NMDA receptor antagonists on probability discounting depend on the order of probability presentation. Pharmacol Biochem Behav. 2016;150–151:31–8. https://doi.org/10.1016/j.pbb.2016.09.004

22. Wozniak DF, Olney JW, Kettinger L, Price M, Miller JP. Behavioral effects of MK-801 in the rat. Psychopharmacology. 1990;101:47–56. https://doi.org/10.1007/BF02253717

23. Burns GA, Ritter RC. The non-competitive NMDA antagonist MK-801 increases food intake in rats. Pharmacol Biochem Behav. 1996;56:145–9. https://doi.org/10.1016/S0091-3057(96)00171-2

24. Yin HH, Knowlton BJ, Balleine BW. Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning. Eur J Neurosci. 2004;19:181–9. https://doi.org/10.1111/j.1460-9586.2004.03905.x

25. Corbit LH, Janak PH. Posterior dorsomedial striatum is critical for both selective instrumental and Pavlovian reward learning. Eur J Neurosci. 2010;31:1312–21. https://doi.org/10.1111/j.1460-9586.2010.07153.x

26. Gremel CM, Costa RM. Orbitofrontal and striatal circuits dynamically encode the shift between goal-directed and habitual actions. Nat Commun. 2013;4:2264. https://doi.org/10.1038/ncomms3264

27. Yin HH, Knowlton BJ, Balleine BW. Blockade of NMDA receptors in the dorsomedial striatum prevents action-outcome learning in instrumental conditioning. Eur J Neurosci. 2005;22:505–12. https://doi.org/10.1111/j.1460-9586.2005.04219.x

28. Parkes SL, Ravassard PM, Cerpa JC, Wolff M, Ferreira G, Coutureau E. Insular and ventrolateral orbitofrontal cortices differentially contribute to goal-directed behavior in rodents. Cereb Cortex. 2018;28:2313–25. https://doi.org/10.1093/cercor/bhx132

29. Parkes SL, Balleine BW. Incentive memory: evidence the basolateral amygdala encodes and the insular cortex retrieves outcome values to guide choice between goal-directed actions. J Neurosci. 2013;33:8753–63. https://doi.org/10.1523/JNEUROSCI.5071-12.2013

30. Miller DW, Abercrombie ED. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull. 1996;40:57–62. https://doi.org/10.1016/0361-9230(95)02144-2

31. Castañé A, Artigas F, Bortolozzi A. The absence of 5-HT1A receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex. Psychopharmacology. 2008;200:281–90. https://doi.org/10.1007/s00213-008-1205-9

32. López-Gil X, Artigas F, Adell A. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action. Int J Neuropsychopharmacol. 2009;12:487–99. https://doi.org/10.1017/S1461145708009267

33. Okada M, Fukuyama K, Ueda Y. Lumisidine inhibits NMDA receptor antagonist-induced functional abnormality of thalamo-cortical glutamatergic transmission via 5-HT7 receptor blockade. Br J Pharmacol. 2019;176:4002–18. https://doi.org/10.1111/bph.14804

34. Callado LF, Hopwood SE, Hancock PJ, Stamford JA. Effects of di- zocilpine (MK 801) on noradrenaline, serotonin and dopamine release and uptake. NeuroReport. 2000;11:173–6. https://doi.org/10.1097/00001756-200001170-00034

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.